VPH – The International Society for In Silico Medicine

Your strategic partner in EC funded projects

Stakeholder Engagement and Outreach

Mapping and involving stakeholders using RRI principles. Design and realisation of targeted engagement activities as interviews, panels, focus groups, and workshops. Find out more from our Info Kit.

Regulatory and Policy support

Monitoring EU/US regulatory trends, advocacy through public consultations (e.g., EU-MDR, AI Act, European Health Data Space), and contributing to policy through workgroups under the VPH-Avicenna Alliance partnership.

Standardisation

Collaborating with FDA, EMA, ISO-IEC and other governing actors to align in silico methods with global standards. VPH has co-authored the Good Simulation Practice and contributed to multiple standards and guidelines.

Communication and Dissemination

Strong track record in engaging different audiences and maximising project visibility. Full in-house C&D support, including strategy, content creation (newsletters, videos, social media, podcast) and EC reporting.

Ecosystem Building & Roadmapping

Ecosystem enabler (e.g., EDITH-CSA and VHT Roadmap), fostering collaboration across academia, industry, regulators, and patients. VPH brings these actors together to accelerate the adoption of digital health innovation.

DISCOVER OUR FULL OFFER

VPH – The International Society for In Silico Medicine is an international non-profit organisation registered in Belgium. With over 40 institutional members and 100+ individual members worldwide, it is a global network of experts dedicated to advancing in silico medicine.

VPH is a trusted partner in EC funded research.

We bridge science, industry, and policy through our strategic partnership with the Avicenna Alliance and collaborate actively with key stakeholders, including the European Commission, European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), Joint Research Centre (JRC), European Patient Forum (EPF), and EUPATI.